These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 16272362)
1. Proteomic scan for tyrosinase peptide antigenic pattern in vitiligo and melanoma: role of sequence similarity and HLA-DR1 affinity. Lucchese A; Willers J; Mittelman A; Kanduc D; Dummer R J Immunol; 2005 Nov; 175(10):7009-20. PubMed ID: 16272362 [TBL] [Abstract][Full Text] [Related]
2. Definition of anti-tyrosinase MAb T311 linear determinant by proteome-based similarity analysis. Willers J; Lucchese A; Mittelman A; Dummer R; Kanduc D Exp Dermatol; 2005 Jul; 14(7):543-50. PubMed ID: 15946243 [TBL] [Abstract][Full Text] [Related]
3. Tyrosinase as an autoantigen in patients with vitiligo. Baharav E; Merimski O; Shoenfeld Y; Zigelman R; Gilbrud B; Yecheskel G; Youinou P; Fishman P Clin Exp Immunol; 1996 Jul; 105(1):84-8. PubMed ID: 8697641 [TBL] [Abstract][Full Text] [Related]
4. Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo. Fishman P; Merimski O; Baharav E; Shoenfeld Y Cancer; 1997 Apr; 79(8):1461-4. PubMed ID: 9118024 [TBL] [Abstract][Full Text] [Related]
5. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase. Riley JP; Rosenberg SA; Parkhurst MR J Immunother; 2001; 24(3):212-20. PubMed ID: 11394498 [TBL] [Abstract][Full Text] [Related]
6. Identification of epitopes on tyrosinase which are recognized by autoantibodies from patients with vitiligo. Kemp EH; Waterman EA; Gawkrodger DJ; Watson PF; Weetman AP J Invest Dermatol; 1999 Aug; 113(2):267-71. PubMed ID: 10469315 [TBL] [Abstract][Full Text] [Related]
7. Oxidized tyrosinase: A possible antigenic stimulus for non-segmental vitiligo autoantibodies. Al-Shobaili HA; Rasheed Z J Dermatol Sci; 2015 Sep; 79(3):203-13. PubMed ID: 26137927 [TBL] [Abstract][Full Text] [Related]
8. Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo. Dorđić M; Matić IZ; Filipović-Lješković I; Džodić R; Sašić M; Erić-Nikolić A; Vuletić A; Kolundžija B; Damjanović A; Grozdanić N; Nikolić S; Pralica J; Dobrosavljević D; Rašković S; Andrejević S; Juranić Z BMC Complement Altern Med; 2012 Jul; 12():109. PubMed ID: 22834951 [TBL] [Abstract][Full Text] [Related]
9. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo). Merimsky O; Shoenfeld Y; Baharav E; Zigelman R; Fishman P Hum Antibodies Hybridomas; 1996; 7(4):151-6. PubMed ID: 9140726 [TBL] [Abstract][Full Text] [Related]
10. Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2). Kemp EH; Gawkrodger DJ; Watson PF; Weetman AP Clin Exp Immunol; 1997 Sep; 109(3):495-500. PubMed ID: 9328128 [TBL] [Abstract][Full Text] [Related]
11. The role of tyrosinase in autoimmune vitiligo. Song YH; Connor E; Li Y; Zorovich B; Balducci P; Maclaren N Lancet; 1994 Oct; 344(8929):1049-52. PubMed ID: 7934446 [TBL] [Abstract][Full Text] [Related]
12. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. Mandelcorn-Monson RL; Shear NH; Yau E; Sambhara S; Barber BH; Spaner D; DeBenedette MA J Invest Dermatol; 2003 Sep; 121(3):550-6. PubMed ID: 12925214 [TBL] [Abstract][Full Text] [Related]
13. Identification of Novel HLA-A*0201-Restricted CTL Epitopes in Chinese Vitiligo Patients. Cui T; Yi X; Guo S; Zhou F; Liu L; Li C; Li K; Gao T Sci Rep; 2016 Nov; 6():36360. PubMed ID: 27821860 [TBL] [Abstract][Full Text] [Related]
14. Identification of the Risk HLA-A Alleles and Autoantigen in Han Chinese Vitiligo Patients and the Association of CD8+T Cell Reactivity with Disease Characteristics. Yi X; Cui T; Li S; Yang Y; Chen J; Guo S; Jian Z; Li C; Gao T; Liu L; Li K Med Sci Monit; 2018 Sep; 24():6489-6497. PubMed ID: 30219821 [TBL] [Abstract][Full Text] [Related]
15. Autoantibodies to human melanocyte-specific protein pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA). Kemp EH; Gawkrodger DJ; Watson PF; Weetman AP Clin Exp Immunol; 1998 Dec; 114(3):333-8. PubMed ID: 9844040 [TBL] [Abstract][Full Text] [Related]
16. Detection of tyrosinase autoantibodies in patients with vitiligo using 35S-labeled recombinant human tyrosinase in a radioimmunoassay. Kemp EH; Gawkrodger DJ; MacNeil S; Watson PF; Weetman AP J Invest Dermatol; 1997 Jul; 109(1):69-73. PubMed ID: 9204957 [TBL] [Abstract][Full Text] [Related]
17. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development. Kittlesen DJ; Thompson LW; Gulden PH; Skipper JC; Colella TA; Shabanowitz J; Hunt DF; Engelhard VH; Slingluff CL J Immunol; 1998 Mar; 160(5):2099-106. PubMed ID: 9498746 [TBL] [Abstract][Full Text] [Related]
18. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Brichard VG; Herman J; Van Pel A; Wildmann C; Gaugler B; Wölfel T; Boon T; Lethé B Eur J Immunol; 1996 Jan; 26(1):224-30. PubMed ID: 8566071 [TBL] [Abstract][Full Text] [Related]
19. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734 [TBL] [Abstract][Full Text] [Related]
20. Autoantibodies against tyrosine hydroxylase in patients with non-segmental (generalised) vitiligo. Kemp EH; Emhemad S; Akhtar S; Watson PF; Gawkrodger DJ; Weetman AP Exp Dermatol; 2011 Jan; 20(1):35-40. PubMed ID: 21158937 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]